1708 completed. 1708 Phase 2, 403 Phase 1, 41 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1708 | Completed 1708 |
| Phase 1 | 403 | Completed 403 |
| Phase 3 | 41 | Completed 41 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Venetoclax After TKI to Target Persisting Stem Cells in CML Venetoclax - Chronic Myeloid Leukemia | Phase 2 | Completed | Thomas Ernst, PD Dr. med. | 10 | 2023-08-31 | 2026-08-18 |
| A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 - Chronic Lymphocytic Leukemia, COVID-19 Infection | Phase 2 | Completed | City of Hope Medical Center | 47 | 2023-08-01 | 2026-09-09 |
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | GCP-Service International West GmbH | 46 | 2023-06-05 | 2026-10-02 |
| Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7" - Acute Myeloid Leukemia | Phase 2 | Completed | Chinese PLA General Hospital | 200 | 2023-03-01 | 2026-01-20 |
| Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte - Acute Myeloid Leukemia | Phase 2 | Completed | Chinese PLA General Hospital | 30 | 2022-12-25 | 2024-11-08 |
| A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients Venetoclax in combination with azacitidine and CAG - Acute Myeloid Leukemia | Phase 2 | Completed | Hematology department of the 920th hospital | 114 | 2022-12-01 | 2025-07-15 |
| Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia cladribine + homoharringtonine + cytarabine - Acute Myeloid Leukemia, Adult | Phase 2 | Completed | First Affiliated Hospital of Zhejiang University | 65 | 2022-10-26 | 2026-02-04 |
| Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Liposomal Annamycin, Cytarabine - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Completed | Moleculin Biotech, Inc. | 22 | 2022-09-29 | 2025-09-30 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) ABC008 - T-cell Large Granular Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Abcuro, Inc. | 21 | 2022-09-28 | 2026-05-06 |
| A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) IPAD, Augmented Reality - Pediatric ALL, Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2022-08-19 | 2026-01-15 |
| Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies Cyclophosphamide, Mesna, Filgrastim - Myeloid Malignancies, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2022-04-08 | 2025-12-19 |
| Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Murine autologous anti-CD19 chimeric antigen receptor T cells - Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Completed | Beijing Boren Hospital | 2 | 2022-03-24 | 2025-05-18 |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm CPX-351 - Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | Completed | French Innovative Leukemia Organisation | 42 | 2022-03-23 | 2024-10-29 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Enasidenib mesylat dose escalation - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Tian Yi Zhang | 17 | 2022-01-12 | 2026-09-03 |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors asciminib, best available treatment - Leukemia, Chronic Myelogenous | Phase 2 | Completed | Novartis Pharmaceuticals | 84 | 2021-12-06 | 2025-04-18 |
| Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma chimeric antigen receptor T cell treatment - T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Completed | Beijing Boren Hospital | 55 | 2021-12-01 | 2025-05-18 |
Showing 20 of 1708. Sign in to see all of them.
Leukemia, Myeloid, Acute (698) · Leukemia, Lymphocytic, Chronic, B-Cell (510) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (452) · Myelodysplastic Syndromes (373) · Lymphoma (272) · Lymphoma, Non-Hodgkin (259) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (228) · Lymphoma, Follicular (217) · Lymphoma, Mantle-Cell (192) · Lymphoma, B-Cell, Marginal Zone (185) · Hodgkin Disease (178) · Lymphoma, Large B-Cell, Diffuse (178) · Burkitt Lymphoma (176) · Multiple Myeloma (159)
Hemic and Lymphatic Diseases (1708) · Neoplasms by Histologic Type (1704) · Hematologic Diseases (1684) · Neoplasms (1646) · Immune System Diseases (993) · Immunoproliferative Disorders (965) · Lymphoproliferative Disorders (955) · Lymphatic Diseases (952) · Leukemia, Myeloid (927) · Pathological Conditions, Signs and Symptoms (918) · Pathologic Processes (912) · Disease Attributes (892) · Leukemia, Lymphoid (845) · Chronic Disease (837)
Cyclophosphamide (274) · Cytarabine (238) · fludarabine phosphate (181) · Rituximab (147) · Filgrastim (132) · Methotrexate (129) · Peripheral Blood Stem Cell Transplantation (125) · Busulfan (118) · Etoposide (112) · fludarabine (108) · Mycophenolic Acid (98) · Cyclosporine (89) · Whole-Body Irradiation (83) · Azacitidine (82) · Tacrolimus (82)
M.D. Anderson Cancer Center (176) · National Cancer Institute (NCI) (107) · Fred Hutchinson Cancer Center (94) · Memorial Sloan Kettering Cancer Center (52) · Novartis Pharmaceuticals (36) · National Heart, Lung, and Blood Institute (NHLBI) (24) · Mayo Clinic (23) · Alliance for Clinical Trials in Oncology (22) · Masonic Cancer Center, University of Minnesota (21) · H. Lee Moffitt Cancer Center and Research Institute (20) · Children's Oncology Group (19) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (19) · Case Comprehensive Cancer Center (18) · Bristol-Myers Squibb (17) · Gruppo Italiano Malattie EMatologiche dell'Adulto (17)
United States (1249) · Germany (163) · Italy (135) · France (132) · Canada (131) · United Kingdom (96) · Spain (78) · Australia (66) · Belgium (48) · South Korea (48) · Austria (47) · Netherlands (47) · Poland (43) · China (41) · Japan (40)
Brenda Sandmaier (13) · Jorge Cortes, MD (12) · Farhad Ravandi-Kashani, MD (9) · Guillermo Garcia-Manero, MD (8) · Kyoo H. Lee, MD (7) · Elias Jabbour, MD (6) · Hagop Kantarjian, MD (6)
PMID 32499241, PMID 23524640, PMID 23065508, PMID 34515338, PMID 35622074, PMID 27209293, PMID 29358183, PMID 30062662, PMID 36184192, PMID 23620574, PMID 25361995, PMID 28835440, PMID 30885996, PMID 31171508, PMID 33242441, PMID 35235189, PMID 17715389, PMID 18596230, PMID 18997171, PMID 19667400, PMID 21403127, PMID 21527516, PMID 21623761, PMID 22133778, PMID 22430088, PMID 23547837, PMID 23886836, PMID 24383844, PMID 24862638, PMID 25527568, PMID 26182309, PMID 26813675, PMID 27355533, PMID 28877686, PMID 29437592, PMID 29618479, PMID 29702001, PMID 30028037, PMID 31023700, PMID 31196847, PMID 32209572, PMID 33394722, PMID 33496754, PMID 33917201, PMID 34048072, PMID 34353848, PMID 34398557, PMID 34432863, PMID 35007144, PMID 35422096
P30CA015704 (41), U10CA031946 (32), P30CA006973 (18), P30CA015083 (17), U10CA032102 (16), P01CA018029 (14), 2008 (13), P30CA043703 (13), 2005 (12), 2009 (12), 2015 (12), P30CA016672 (12), U10CA098543 (11), 2016 (10), U01CA070095 (10)